Athira Pharma reported Q2 2025 financial results, focusing on cost reduction and advancing its ALS drug candidate ATH-1105. The company narrowed its net loss, reduced R&D expenses, and completed a Phase 1 clinical trial, but faces challenges in securing partnerships and maintaining cash reserves.

Athira Pharma announced positive results from a Phase 1 clinical trial of its drug candidate ATH-1105 in healthy volunteers, supporting continued development for the potential treatment of amyotrophic lateral sclerosis (ALS). The company plans to initiate a clinical trial in ALS patients in late 2025.

Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024 Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024